Table 2. Major differences in HF-PEF treatment recommendations between the ESC and ACCF/AHA Guidelines.

	2012 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	2013 ACCF/AHA Guideline for the management of heart failure
Class 1	No treatment has yet been shown to reduce morbidity and mortality	Blood pressure control (LOE B)
		Diuretics for symptoms relief (LOE C)
Class 2a		Coronary revascularization in CAD (LOE C)
		a. Symptomatic or
		b. Myocardial Ischaemia
		AF management (LOE C)
		If hypertension use of ACE inibitors and beta blockers (LOE C)
		Use of PUFA in NYHA 2-4, unless controindicated (LOE B)
Class 2b		Use of ARBs (LOE C)

AF: atrial fibrillation; ARBs: angiotensinreceptor blockers; CAD: coronary artery disease; HF-PEF: Heart failure with preserved ejection fraction; LOE: level of evidence; PUFA: omega-3 polyunsatured fatty acid.